-
Clinical Infectious Diseases, August 2019 Due to complex interactions between HIV, antiretroviral therapy, and the chronic immune activation and inflammation that can be seen in people living with HIV, there is an increased risk for cardiovascular diseases including acute myocardial infarctions (heart attacks).
Aug 15, 2019
-
Journal of Acquired Immune Deficiency Syndrome, August 2019 Although ART suppresses plasma viremia to levels below the level of detection, reservoirs of latently infected cells that lead to viral rebound if ART is stopped persist in people living with HIV.
Aug 15, 2019
-
PERSISTENCE OF HIV DNA IN CEREBROSPINAL FLUID AND NEUROLOGICAL IMPLICATIONS
Journal of Clinical Investigation, July 2019 The persistence of HIV in sanctuary sites in the human body even in the presence of antiretroviral therapy (ART) is a potential barrier to HIV remission and cure.
Jul 15, 2019
-
OPTIONS STUDY (A5241) ASKS WHETHER NRTIS ARE ESSENTIAL IN SALVAGE REGIMENS
Journal of Infectious Diseases, May 2019 When people with HIV develop resistance to antiretroviral medications, their clinicians often prescribe previously used nucleoside reverse transcriptase inhibitors (NRTIs), along with other drugs, in the new “salvage” regimen, reasoning that the NRTIs may improve the chances of treatment response.
May 28, 2019
-
DO ELITE CONTROLLERS REQUIRE ART FOR SECONDARY BENEFITS?
Clinical Infectious Diseases, May 2019 There is an ongoing debate in the literature about whether elite controllers require antiretroviral therapy (ART) for secondary benefits, including control for low-level viral replication and reduction of inflammation.
May 25, 2019
-
Lancet Digital Health, May 2019 (ACTG) A5288 (MULTI-OCTAVE) is one of the first studies to look at interventions for medication adherence in lower-income and middle-income countries (LMICs) for individuals failing second line therapy.
May 01, 2019
-
NWCS 399: CT AS NON-INVASIVE ASSESSMENT OF FAT QUALITY
The Journal of Clinical Endocrinology & Metabolism, April 2019 Fat quality or function contributes to risk for diseases such as heart disease, fatty liver disease, and diabetes, and may be as important as fat quantity when assessing the risk of poor health outcomes.
Apr 11, 2019
-
UNDERLYING FACTORS ASSOCIATED WITH RACIAL DISPARITIES IN HIV OUTCOMES
Open Forum Infectious Diseases, February 2019 Racial/ethnic disparities in HIV outcomes have persisted despite effective antiretroviral therapy.
Feb 01, 2019
-
DTG/3TC IS DURABLE INITIAL THERAPY THROUGH 48 WEEKS
Journal of Antimicrobial Chemotherapy, January 2019 This study is an important subset analysis of the AIDS Clinical Trials Group study A5353, which demonstrated the efficacy and safety of dolutegravir and lamivudine for the initial treatment of HIV-1 infection at week 24 in individuals with HIV-1 RNA levels 1000-500 000 copies/mL for the first time.
Jan 18, 2019
